Geptanolimab
Modify Date: 2024-01-13 17:46:20
Geptanolimab structure
|
Common Name | Geptanolimab | ||
|---|---|---|---|---|
| CAS Number | 2348469-43-0 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of GeptanolimabGeptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer[1]. |
| Name | Geptanolimab |
|---|
| Description | Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Geptanolimab (CBT-501) 与人 (KD=505 pM) 和猕猴 (KD=7.2 nM) 的 PD-1 具有高度特异性结合[ 1]。 Geptanolimab 增强混合淋巴细胞反应 (MLR) 中的人 T 细胞活化，增加 IL-2 和 INF-γ 的释放[1]。 |
| In Vivo | Geptanolimab (CBT-501; ip; 每两周一次, 持续6周; MC38同系肿瘤模型小鼠) 具有抗肿瘤活性，抑瘤率达到 83%[1]。 |
| References |
| No Any Chemical & Physical Properties |